Prostate Cancer Awareness and Initiative for Screening in the European Union
NCT06424275 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 20000
Last updated 2025-08-15
Summary
PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer screening in Europe and enhance patient outcomes. PRAISE-U advocates for EU member states to offer exceptional clinical standards, incorporating cutting-edge personalized approaches to enable timely detection of prostate cancer in individuals who can benefit from early treatment. To assess the functionality, feasibility, and long-term viability of a risk-based algorithm, the consortium will collaborate with pilot sites in Spain, Poland, Ireland, and Lithuania.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Risk-based screening algorithm
Risk-based screening algorithm
Sponsors & Collaborators
- collaborator OTHER
-
European Randomised Study of Screening for Prostate Cancer
collaborator UNKNOWN -
Region MidtJylland Denmark
collaborator OTHER -
Institute of Health Information and Statistics of the Czech Republic
collaborator OTHER_GOV -
UMC Utrecht
collaborator OTHER -
EUROPEAN CANCER ORGANISATION
collaborator UNKNOWN -
Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii
collaborator UNKNOWN -
Narodowy Instytut Zdrowia Publicznego
collaborator UNKNOWN -
Conselleria de Sanidade de Galicia
collaborator UNKNOWN -
Althaia Xarxa Assistencial Universitària de Manresa
collaborator OTHER -
Vastra Gotaland Region
collaborator OTHER_GOV -
Region Skane
collaborator OTHER -
National Cancer Institute (NCI)
collaborator NIH -
University Ghent
collaborator OTHER -
Health Service Executive, Ireland
collaborator OTHER -
Estonian Urological Association
collaborator UNKNOWN -
University College Dublin
collaborator OTHER -
WONCA Europe
collaborator UNKNOWN -
Movember Foundation
collaborator OTHER -
International Agency for Research on Cancer
collaborator OTHER -
European Society of Urogenital Radiology
collaborator OTHER -
Europa UOMO
collaborator UNKNOWN -
Czech Urological Society
collaborator UNKNOWN -
European Association of Urology Research Foundation
lead OTHER
Principal Investigators
-
Hendrik Van Poppel, Prof · European Association of Urology and KULeuven
-
Monique J Roobol, Prof · Erasmus MC Cancer Institute Dep of Urology and European Association of Urology
Eligibility
- Min Age
- 50 Years
- Max Age
- 69 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-06-01
- Primary Completion
- 2026-04-01
- Completion
- 2026-04-01
Countries
- Ireland
- Lithuania
- Poland
- Spain
Study Locations
More Related Trials
-
Micro-RNA Expression Profiles in High Risk Prostate Cancer
NCT01220427 ·Status: TERMINATED
-
DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
NCT07265414 ·Status: ACTIVE_NOT_RECRUITING
-
All-in-One Prostate Cancer Staging with MRI
NCT06071195 ·Status: RECRUITING
-
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
NCT01672411 ·Status: COMPLETED
-
Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients
NCT03156244 ·Status: COMPLETED
-
An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum
NCT05384002 ·Status: COMPLETED
-
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT04404894 ·Status: ACTIVE_NOT_RECRUITING
-
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
NCT04964271 ·Status: ACTIVE_NOT_RECRUITING
-
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
NCT02766543 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer
NCT03677414 ·Status: UNKNOWN
-
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
NCT06820333 ·Status: RECRUITING
-
Prospective Prostate Cancer and Patient-reported Outcomes Registry
NCT04694924 ·Status: RECRUITING
-
Early Detection of Prostate Cancer
NCT04556916 ·Status: RECRUITING ·Phase: NA
-
Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)
NCT01191931 ·Status: COMPLETED
-
Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer
NCT06468332 ·Status: RECRUITING
-
Prostate Active Surveillance Study
NCT00756665 ·Status: RECRUITING
-
Precision-Based Genomics in Prostate Cancer
NCT04706663 ·Status: RECRUITING
-
Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer
NCT04702633 ·Status: COMPLETED
-
Prostate Cancer Upgrading Reference Set
NCT02189486 ·Status: COMPLETED
-
Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer
NCT05681416 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging and Biomarkers
NCT01864135 ·Status: COMPLETED ·Phase: NA
-
Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI
NCT02002455 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
NCT03423303 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients
NCT05447637 ·Status: COMPLETED
-
Prospective Evaluation of Proclarix® Test to Improve Risk Stratification in Men Scheduled for MpMRI and Prostate Biopsy in Cantonal Hospital Aarau
NCT06637267 ·Status: RECRUITING